Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Beijing Shadong Biotechnology
Beijing, Beijing, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Beijing Shadong Biotechnology is a clinical-stage biopharmaceutical company based in China, specializing in the development of recombinant protein therapeutics for cancer. The company's flagship product, CPT (Circularly Permuted TRAIL), is a first-in-class pro-apoptotic drug that targets death receptors on tumor cells. CPT has completed Phase 3 clinical trials for multiple myeloma and has been submitted for regulatory approval in China. Shadong's research focuses on leveraging the TRAIL pathway to provide targeted, low-toxicity treatments for hematological malignancies.
- Therapeutic areas
- Oncology
- Modalities
- Recombinant proteinBiologic
- Industry
- Biotech
Beyond the preview
Go deeper on Beijing Shadong Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beijing Shadong Biotechnology.